MDR1和Anxa2在乳腺癌组织中的表达与侵袭转移的关系研究

Correlation of MDR1 and Anxa2 Overexpression with Breast Cancer Invasion and Metastasis

目的:探讨乳腺癌组织中多药耐药基因(MDR1)和膜联蛋白(Anxa2)表达的相关性及其与乳腺癌转移的关系。方法:应用荧光定量PCR的方法检测20例配对的乳腺导管内癌、100例乳腺浸润性导管癌、70例癌旁正常组织中MDR1和Anxa2 mRNA的相对表达情况。结果:MDR1 mRNA在乳腺导管内癌中的表达水平明显高于癌旁正常组织(P=0.005),乳腺浸润性导管癌组织中mRNA的表达明显高于癌旁正常组织(P=0.017)和导管内癌(P=0.019 6)。Anxa2 mRNA在乳腺导管内癌中表达与癌旁正常组织相比无显著性差异(P=0.188 9),但是在乳腺浸润性导管癌组织中的表达明显高于导管内癌(P=0.000 8)和癌旁正常组织(P<0.000 1);MDR1和Anxa2 mRNA的表达升高均与患者出现淋巴结转移有关(P<0.01);2种基因在乳腺浸润性导管癌中的表达呈正相关(P<0.000 1)。结论:在肿瘤进展过程中,MDR1和Anxa2 mRNA表达上调与乳腺癌的淋巴结转移有关,二者之间表达具有正相关提示肿瘤细胞的多药耐药的获得和肿瘤侵袭转移之间有着密切联系。

Objective： To investigate the correlation between MDR1 and Anxa2 mRNA expression and metastasis of breast cancer in large sample. Methods： Real-time reverse transcription-polymerase chain reaction （ RT-PCR ） was used to examine expression levels of MDR 1and Anxa2 mRNA in 20 cases of primary ductal carcinoma in situ and normal breast tissues, as well as 100 cases of invasive ductal carcinoma, and 70 cases of normal tissue. Result： MDR1 mRNA expression in ductal carcinoma in situ was significantly higher than that in the paired normal breast tissue （ P = 0.005 ）, MDR1 mRNA expression in invasive ductal carcinoma was significantly higher than that in ductal carcinoma （ P = 0.0051 ） and the normal breast cancer tissues （ P = 0.0196 ）. No significant difference in Anxa2 mRNA expression was detected between ductal carcinoma in situ and the paired normal breast tissue. Anxa2 mRNA expression in invasive ductal carcinoma was significantly higher than that in ductal carcinoma （ P = 0.0008 ） and normal breast cancer （ P 〈 0.0001 ）. Overexpression of MDR1 and Anxa2 mRNA was correlated with lymph node metastasis （ P 〈 0.01 ）. MDR1 mRNA expression was also correlated with Anxa2 in invasive ductal carcinoma. Conclusion： MDR1 and Anxa2 overexpression are closely associated with the invasion and metastasis of breast cancer and the correlation between MDR1 and Anxa2 indicates a functional linkage between cancer metastasis and multidrug resistance during cancer progression.